ALK plus NSCLC ALK Inhibitors symbolize Progress in Cancer Medicine

被引：0
|
作者：
Kohl, Angelika
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷 / 7-8期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：435 / 435
页数：1
相关论文
共 50 条
  • [1] ALK Inhibitors in the Treatment of ALK Positive NSCLC
    Khan, Muhammad
    Lin, Jie
    Liao, Guixiang
    Tian, Yunhong
    Liang, Yingying
    Li, Rong
    Liu, Mengzhong
    Yuan, Yawei
    FRONTIERS IN ONCOLOGY, 2019, 8
  • [2] Analysis of resistance mechanisms to ALK kinase inhibitors in ALK plus NSCLC patients.
    Doebele, Robert Charles
    Aisner, Dara L.
    Le, Anh T.
    Berge, Eamon M.
    Pilling, Amanda B.
    Kutateladze, Tatiana G.
    Weickhardt, Andrew James
    Franklin, Wilbur A.
    Varella-Garcia, Marileila
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Brigatinib Effective in ALK plus NSCLC
    Leslie, Mitch
    CANCER DISCOVERY, 2017, 7 (01) : 4 - 5
  • [4] A Novel Nonreciprocal/Reciprocal ALK Translocation Cause ALK plus in NSCLC
    Chen, Xianguo
    Xu, Bo
    Fu, Fangni
    Cai, Ke
    Yu, Zhaonan
    LUNG CANCER, 2021, 158 : 162 - 163
  • [5] Description of ALK plus NSCLC patient characteristics and ALK testing patterns
    Wakelee, Heather A.
    Sasane, Medha
    Zhang, Jie
    Macalalad, Alexander R.
    Galebach, Philip J.
    Jarvis, John
    Kageletry, Andrew James
    Huang, Qing
    Culver, Kenneth W.
    Wu, Eric Qiong
    Guerin, Annie
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Description of ALK plus NSCLC Patient Characteristics and ALK Testing Patterns
    Wakelee, H. A.
    Sasane, M.
    Zhang, J.
    Macalalad, A. R.
    Galebach, P.
    Jarvis, J.
    Kageleiry, A.
    Huang, Q.
    Culver, K.
    Wu, E. Q.
    Guerin, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S60 - S61
  • [7] Sequencing of ALK Inhibitors in ALK plus Non-Small Cell Lung Cancer
    Gadgeel, Shirish M.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (06)
  • [8] ALK inhibitors in the treatment of advanced NSCLC
    Gridelli, Cesare
    Peters, Solange
    Sgambato, Assunta
    Casaluce, Francesca
    Adjei, Alex A.
    Ciardiello, Fortunato
    CANCER TREATMENT REVIEWS, 2014, 40 (02) : 300 - 306
  • [9] Indirect Naive Comparison of ALK Inhibitors for ALK plus Non-Small Cell Lung Cancer (NSCLC) Post-Crizotinib Failure
    Reckamp, Karen L.
    Huang, Joice
    Huang, Hui
    Moore, Yan
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S313 - S314
  • [10] Background of patients (pts) with ALK rearranged (ALK plus ) non-small-cell lung cancer (NSCLC), and efficacy and safety of ALK inhibitors (ALK-Is) in actual clinical practice: Multicenter retrospective study
    Ito, K.
    Saiki, H.
    Sakaguchi, T.
    Hayashi, K.
    Nishii, Y.
    Watanabe, F.
    Hataji, O.
    Okano, T.
    Naito, M.
    Ibata, H.
    Fujiwara, A.
    Yoshida, M.
    Itani, H.
    Tanigawa, M.
    Kobayashi, H.
    ANNALS OF ONCOLOGY, 2015, 26 : 140 - 140
12345